It is now commonly admitted that the so-called (most) neglected tropical diseases have been given little attention. According to World Health Organization, neglected diseases are hidden diseases as they affect almost exclusively extremely poor populations living in remote areas beyond the reach of health service. The European Parliament recognised that, to our shame, Neglected Diseases have not received the attention they deserve from EU actions. In the Millennium Development Goals they were given very little attention and mentioned just as other disease. Investing in drugs for these diseases is thought to be not marketable or profitable. However, despite their low mortality, neglected diseases are causing severe and permanent disabilities and deformities affecting approximately 1 billion people in the world, yielding more than 20 millions of Disability Adjusted Life Years (56.6 million according to Lancet's revised estimates) and important socio-economic losses. Urgent pragmatic and efficient measures are needed both at international and national levels.
Introduction
At the dawn of the third millennium, while human rights and health equity are on all international agendas, millions of forgotten people are suffering from a dozen of neglected diseases (NDs). According to The World Health Organization (WHO), NDs are hidden diseases as they affect almost exclusively extremely poor populations living in remote areas beyond the reach of health services [1] . The European Parliament recognised that "to our shame, Neglected Diseases have not received the attention they deserve from EU actions" [2] . Focusing on the "big killers" like HIV/AIDS, malaria and tuberculosis, the Millennium Development Goals (MDG) and other initiatives have generally given very little attention to the most neglected diseases, often mentioned just as "other disease" (Table 1 ) [3] . Criticizing the "inertia" and the delay taken in the response to the infectious diseases, the humanitarian organization Médecins sans Frontière (MSF) has been continuously attracting the international attention to stimulate more interest in the development and provision of treatments for the most neglected diseases [4] . Meanwhile, beyond mortality figures, NDs continue to cause severe and permanent disabilities and deformities affecting more than a billion people in the world and breeding millions of disability adjusted life years (DALYs) and important economic losses. Indeed, lymphatic filariasis(LF), leishmaniasis, schistosomiasis, Buruli ulcer, cholera, cysticercosis, dracunculiasis (guineaworm disease), foodborne trematode infections, hydatidosis, soil-transmitted helminthiasis (ascariasis, trichuriasis, hookworm diseases), trachoma, trypanosomiasis (sleeping sickness), onchocerciasis, Chagas disease, dengue and others [Additional file 1] are responsible for impaired childhood growth, mental retardation, blind-ness, amputation and diverse disability conditions and hence they are impeding human development of many countries of Africa and Latin America (Tables 2 and  3 ) [1, [5] [6] [7] [8] . The situation being commonly admitted, it remains that urgent and efficient strategies are needed at local, national and international levels in order to reduce the growing burden of these diseases of the poor.
Neglected diseases afflicting marginalised populations: Challenges and perspectives
Neglected Diseases are given low priority because they have low mortality, they occur almost exclusively in poor developing countries and essentially, because they offer negligible marketable and profitable issues. As stressed by the European Parliament Report in 2005, "No research is currently being carried out into the most neglected diseases which mainly affect developing countries...there is a chronic shortage of investment in research and development in poverty-related diseases and in the developing countries themselves to obtain medicines which meet the needs of those countries" [2] .
For the pharmaceutical industry, which carries out the main research and development for new drugs, it is too costly and risky to invest in drugs for neglected diseases occurring essentially in low-income countries where public spending on drugs is less than US$6 (sub-Saharan Africa) compared to around US$ 240 spent in countries of the Organization for Economic Cooperation and Development (OECD) [9] . It is estimated that, less than 10% of the world's biomedical research funds are dedicated to problems dealing with 90% of the world's burden of disease and, of all drugs in development for all neglected diseases in 1999-2000, 18 R&D projects were clinical development, compared to 2100 compounds for all other diseases [1, 2] . Between 1975 and 2004, among the 1556 new molecules of drugs marketed in the world, only 21 were intended for the neglected diseases (8 for malaria, 3 for tuberculosis and only 10 for the whole set of most neglected diseases) [4] . Another study found that, of the 1393 new chemical entities marketed between 1975 and 1999, only 16 were for tropical diseases and tuberculosis, yielding a 13-fold greater chance for a drug to be marketed for central-nervous-system disorders or cancer than for a neglected disease (Table 4) [9] .
Despite the dilemma created by the pharmaceutical industry (treatment-profit), the responsibility is shared by However, this international strategy is insufficient without the national and local implication. National health decision makers, non governmental organizations (NGOs), research institutions, community groups and individuals must adhere to these global initiatives. Many countries, being heavily indebted, affect less than 1% of the national global budget to health, and few governments are putting science, technology, and innovation at the centre of their strategies and, in the meantime, war and conflicts are financed at the expense of health services. For instance, in 1999, the governments of sub-Saharan Africa dedicated US$7 billion to military spending, whereas, diverting just 15% of this would have raised more than one US$ billion, enough to treat millions of patients affected by neglected diseases [13, 14] . It is also worth stressing that, in the absence of reporting and surveillance, the available statistics on the burden of NDs are sometimes very different as indicated in Tables 2 and 3 .
To overcome this odd situation and in order to reduce the burden of neglected diseases afflicting mainly poor popu- 
Conclusion
In many developing countries, millions of people live with less than one dollar a day and on fragile and often remote rural ecosystems, most of them lack access to basic health services and safe drinking water and sanitation (vectors that transmit NDs thrive on these ideal conditions). Trapped in the vicious circle of underdevelopmentpoverty-health inequity, these populations constitute exhausted "preys" for "predators" such as HIV/AIDS, malaria, tuberculosis and a multitude of the so-called neglected diseases. The growing attention given to the "Big Three Killers" should not shadow the suffering that neglected diseases are causing to millions of people who can afford, at best, archaic drugs, some of which are toxic, ineffective or difficult to administer.
In the era of science and high technology, while regular meetings are held worldwide to discuss human rights and various forms, causes and consequences of health inequities, it is a shame that poor populations living in developing countries are denied access to adequate and affordable treatment against NDs. Urgent actions are needed to develop new drugs and vaccines that are efficient and accessible. A big challenge is addressed to national and international decision makers but it is worth trying.
